Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. Rix U, et al. Among authors: colinge j. Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890374
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. Winter GE, et al. Among authors: colinge j. Nat Chem Biol. 2012 Nov;8(11):905-912. doi: 10.1038/nchembio.1085. Epub 2012 Sep 30. Nat Chem Biol. 2012. PMID: 23023260 Free PMC article.
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo JV, Bennett KL, Valent P, Superti-Furga G. Rix U, et al. Among authors: colinge j. PLoS One. 2013 Oct 10;8(10):e77155. doi: 10.1371/journal.pone.0077155. eCollection 2013. PLoS One. 2013. PMID: 24130846 Free PMC article.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. Hantschel O, et al. Among authors: colinge j. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7. Proc Natl Acad Sci U S A. 2007. PMID: 17684099 Free PMC article.
Charting the molecular network of the drug target Bcr-Abl.
Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Köcher T, Mechtler K, Bennett KL, Superti-Furga G. Brehme M, et al. Among authors: colinge j. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7414-9. doi: 10.1073/pnas.0900653106. Epub 2009 Apr 20. Proc Natl Acad Sci U S A. 2009. PMID: 19380743 Free PMC article.
115 results